At a glance
ClinicalIndex Comparison RecordN/ACompleted· 138 enrolled
Drug / intervention
JUVEDERM® Ultra XC +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Controlled, Multi-center Study of the Safety and Effectiveness of JUVEDERM® Ultra XC Injectable Gel Versus Belotero Balance® for Perioral Lines
In Brief
A clinical study evaluating JUVEDERM® Ultra XC and Belotero Balance® for Patients With Moderate to Severe Perioral Lines. Completed, enrolled 138 participants across 1 site.
Detailed Summary
A prospective, randomized, controlled, multi-center study of the safety and effectiveness of JUVEDERM® Ultra XC injectable gel versus Belotero Balance® for perioral lines
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionAug 2014
TodayJul 2026
First PostedOct 28, 2013
Enrollment StartOct 21, 2013
Primary CompletionAug 4, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.7 years ago
Interventions
JUVEDERM® Ultra XCdevice
Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
Belotero Balance®device
Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).